Recent briefings covering the 30-day period through 2026-07-27 recorded no material discrete corporate events, new regulatory disclosures, or new corporate announcements for AbbVie Inc. Successive briefs dated 2026-06-09 through 2026-07-19 each noted the absence of new filings beyond routine continuations, indicating a period of limited public disclosure activity in the weeks preceding this report [Brief - 2026-07-27].
For the trailing twelve months ending 2026-06-30, AbbVie recorded revenue of $64.39 billion, representing year-over-year growth of 10.2%. Net income for the same period was $6.31 billion, with a net margin of 9.80%. Gross margin stood at 65.73% and operating margin at 26.20%. Earnings per share grew 290.4% year-over-year on a TTM basis. The company carried $6.57 billion in cash against total debt of $64.50 billion, resulting in a net debt position. The reported P/E ratio was 69.24 [SEC 10-Q - ABBV - 2026-06-30].
Institutional ownership data from the most recent 13F filings reflects divergent positioning among notable managers. Millennium Management (Izzy Englander) added 61% to its ABBV position, while Bridgewater Associates (Ray Dalio) increased its holding by 114%. Conversely, Citadel (Ken Griffin) reduced its position by 11% and AQR Capital (Cliff Asness) reduced its position by 23% [SEC 13F - Millennium - Q2 2026] [SEC 13F - Bridgewater - Q2 2026] [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026].
The prevailing macroeconomic environment features a 10-year US Treasury yield of 4.75% and a 2-year yield of 4.28%, reflecting a normal yield curve with a spread of 47 basis points [FRED DGS10] [FRED DGS2]. This rate configuration is relevant context for a company carrying a substantial debt load, as AbbVie's $64.50 billion in total debt is situated within a sustained elevated interest rate environment.